APA (7th ed.) Citation

R, A., JB, G., HJL, H., JFE, M., JB, M., AK, M., . . . M, N. (2025). COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristics. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 40(8), 1559. https://doi.org/10.1093/ndt/gfaf022

Chicago Style (17th ed.) Citation

R, Agarwal, et al. "COmbinatioN Effect of FInerenone AnD EmpaglifloziN in Participants with Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint (CONFIDENCE) Trial: Baseline Clinical Characteristics." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association 40, no. 8 (2025): 1559. https://doi.org/10.1093/ndt/gfaf022.

MLA (9th ed.) Citation

R, Agarwal, et al. "COmbinatioN Effect of FInerenone AnD EmpaglifloziN in Participants with Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint (CONFIDENCE) Trial: Baseline Clinical Characteristics." Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 40, no. 8, 2025, p. 1559, https://doi.org/10.1093/ndt/gfaf022.